PREF-NET: a patient preference and experience study of lanreotide autogel administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumours in the UK
Open Access
- 29 February 2024
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 32 (3) , 1-12
Abstract
Purpose: PREF-NET reported patients’ experience of Somatuline® (lanreotide) Autogel® (LAN) administration at home and in hospital among patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Methods: PREF-NET was a multicentre, cross-sectional study of UK adults (aged ≥ 18 years) with GEP-NETs receiving a stable dose of LAN, which comprised of (1) a quantitative online survey, and (2) qualitative semi-structured interviews conducted with a subgroup of survey respondents. The primary objective was the description of overall patient preference for home versus hospital administration of LAN. Secondary objectives included describing patient-reported opinions on the experience and associated preference for each administration setting, and the impact on healthcare utilisation, societal cost, activities of daily living and health-related quality of life (HRQoL). Results: In the primary analysis (80 patients; mean age 63.9 years), 98.7% (95% confidence interval [CI]: 96.1–100.0) of patients preferred to receive LAN at home, compared with 1.3% (95% CI: 0.0–3.9) who preferred the hospital setting. Among participants, over half (60.3%) received their injection from a non-healthcare professional. Most patients (79.5% [95% CI: 70.5–88.4]) reported a positive effect on HRQoL after the switch from hospital to home administration. Qualitative interviews (20 patients; mean age 63.6 years) highlighted that patients preferred home administration because it improved overall convenience; saved time and costs; made them feel more comfortable and relaxed, and less stressed; and increased confidence in their ability to self-manage their treatment. Conclusion: Almost all patients preferred to receive LAN treatment at home rather than in hospital with increased convenience and psychological benefits reported as key reasons for this preference.Keywords
Funding Information
- Ipsen Fund
This publication has 18 references indexed in Scilit:
- An international simulated-use study to assess nurses’ preferences between two lanreotide syringes for patients with neuroendocrine tumours or acromegaly (PRESTO 3)Journal of Endocrinological Investigation, 2023
- OPERA: perception of information in patients with gastroenteropancreatic neuroendocrine tumors on lanreotide autogelEuropean Journal of Endocrinology, 2023
- PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or AcromegalyAdvances in Therapy, 2022
- Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature reviewEndocrine, 2022
- Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumoursJournal of Neuroendocrinology, 2022
- Impacts on health outcomes and on resources utilization for anticancer drugs injection at home, a complex intervention: a systematic reviewSupportive Care in Cancer, 2021
- Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension studyEndocrine, 2020
- Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational studyDigestive and Liver Disease, 2016
- Economic comparison between Hospital at Home and traditional hospitalization using a simulation‐based approachJournal of Enterprise Information Management, 2013
- Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)Alimentary Pharmacology & Therapeutics, 2011